Tuberculosis Infection
36
10
13
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.8%
1 terminated out of 36 trials
90.0%
+3.5% vs benchmark
8%
3 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (36)
Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
Window Prophylaxis for Pediatric Tuberculosis Prevention Trial
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
Effects of Tuberculosis Infection on Development and Function of the Placenta
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
Immunological Biomarkers in Tuberculosis Management
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age